Summit Securities Group’s Collegium Pharmaceutical COLL Stock Holding History

Summit Securities Group’s Portfolio COLL Stock Details COLL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$57.5K	Buy	+2,635	New	+$76.9K	0.01%	547

Other funds holding COLL

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return

Royce & Associates New York $11B AUM 39.4% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Peregrine Capital Management Minneapolis, Minnesota $2.95B AUM 28.43% 1-Year Est. Return

Ballast Asset Management Dallas, Texas $230M AUM 34.36% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Bessemer Group Woodbridge, New Jersey $72.8B AUM 32.97% 1-Year Est. Return

Summit Securities Group's COLL Position: Q3 2026 in Review

Summit Securities Group opened a new position in Collegium Pharmaceutical (COLL) in Q3 2026: 2,635 shares worth $57.5K. The stake represents 0.01% of the portfolio and ranks #547 among its holdings.

102 funds tracked by Wall St. Rank hold COLL as of Q3 2026.

Summit Securities Group held 2,635 shares of Collegium Pharmaceutical worth $57.5K as of Q3 2026.
Collegium Pharmaceutical was a new Summit Securities Group position in Q3 2026.
Collegium Pharmaceutical made up 0.01% of Summit Securities Group's portfolio in Q3 2026, its #547 holding.
102 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q3 2026.

Based on Summit Securities Group's 13F filing for Q3 2026, filed 5 Nov 2026.